- Conditions
- Major Depressive Disorder
- Interventions
- Zelquistinel
- Drug
- Lead sponsor
- Syndeio Biosciences, Inc
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 32
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Montclair, California + 27 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–5
of 5
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Major Depressive Disorder
- Interventions
- Zelquistinel
- Drug
- Lead sponsor
- Syndeio Biosciences, Inc
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Encino, California + 30 more
- Conditions
- Major Depressive Disorder
- Interventions
- AGN-241751, Placebo
- Drug
- Lead sponsor
- Syndeio Biosciences, Inc
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 226 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 5
- States / cities
- Phoenix, Arizona • Garden Grove, California • Atlanta, Georgia + 2 more
- Conditions
- Healthy Volunteers in Fed and Fasted State
- Interventions
- Zelquistinel 3 mg, Zelquistinel 10 mg
- Drug
- Lead sponsor
- Syndeio Biosciences, Inc
- Industry
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Depressive Disorder, Major
- Interventions
- AGN-241751, Placebo
- Drug
- Lead sponsor
- Syndeio Biosciences, Inc
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 251 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 25
- States / cities
- Fayetteville, Arkansas • Cerritos, California • Encino, California + 20 more